REGN
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc historical holders
total: 8
Scion Asset Management Regeneron Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q3
Michael Burry has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2025 Q2. According to 2025 Q3 report, Michael Burry doesn't hold any shares. The fund/company first acquired REGN in 2025 Q2, initially purchasing 15,000 shares. Since the initial investment, Scion Asset Management has made 1 more transaction in this position.
When did Michael Burry exit their REGN position?
Michael Burry no longer holds Regeneron Pharmaceuticals Inc (REGN). They sold off their entire position in 2025 Q3, closing out an investment that began in 2025 Q2.
When did Michael Burry first invest in REGN?
Michael Burry first invested in Regeneron Pharmaceuticals Inc (REGN) in 2025 Q2 at the reported quarter-end price of $525.00 per share, acquiring 15,000 shares in their initial purchase.
What is Michael Burry's average cost basis for REGN?
Based on historical transaction data, Michael Burry's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $525.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $525.00
- Weighted AVG sell price:
- $525.00
REGN transactions history by Scion Asset Management
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$525.00
|
|
-100% (-15,000)
|
-14%
|
|
2025 Q2
|
14.00%
|
15,000
|
$525.00
|
$7,875,000
|
new
|
+14%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.